First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Study Overview

• Status: Recruiting
• Conditions: Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma
• Intervention / Treatment: Drug: EMB07

Detailed Description

This is a phase I, multicenter, open label, dose escalation, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose for EMB-07 in patient with locally advanced/metastatic solid tumors or relapse/refractory Lymphoma . Pharmacokinetics, pharmacodynamics, immunogenicity and response will also be assessed.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Sai Lou; Phone Number: +8613758235260; Email: slou@epimab.com
• Study Contact Backup: Name: Junqiang He; Phone Number: +8618302157016; Email: jqhe@epimab.com

Study Locations

• Australia
  • Victoria
    • Frankston, Victoria, Australia
      • Recruiting
      • Peninsula and South Eastern Haematology and Oncology Group
      • Principal Investigator: Ganju
  • Western Australia
    • Nedlands, Western Australia, Australia
      • Recruiting
      • One Clinical Research
      • Principal Investigator: Ariyapperuma
• China
  • Baoding, China
    • Recruiting
    • Affiliated Hospital of Hebei University
    • Contact: Youchao Jia
  • Beijing, China
    • Recruiting
    • Cancer Hospital Chinese Academy of Medical Sciences
    • Principal Investigator: Yuankai Shi
  • Bengbu, China
    • Recruiting
    • The First Affiliated Hospital of Bengbu Medical College
    • Contact: Huan Zhou
    • Contact: Yanli Yang
  • Guangzhou, China
    • Recruiting
    • Zhujiang Hospital of Southern Medical University
    • Contact: Sanfang Tu
  • Harbin, China
    • Recruiting
    • The Affiliated Tumour Hospital of Harbin Medical University
    • Contact: Qingyuan Zhang
  • Shandong, China
    • Recruiting
    • Shandong Cancer Hospital
    • Contact: Yuping Sun
    • Contact: Zengjun Li
  • Tianjin, China
    • Recruiting
    • Tianjin Medical University Cancer Institue & Hospital
    • Contact: Lanfang Li
  • Hunan
    • Changsha, Hunan, China
      • Recruiting
      • Hunan Cancer Hospital
      • Contact: Quchang Ouyang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.
2. Male or female, and aged ≥ 18 years
3. Treatment group A: Patients with histologically or cytologically locally advanced unresectable or metastatic solid tumors limiting to triple-negative breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, prostate cancer, bladder cancer, and uterus cancer. Treatment group B: Patients with histologically or cytologically relapse/refractory lymphoma limiting to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL).
4. Treatment group A: Standard therapies do not exist, or are no longer effective, or are not tolerable or accessible to the patient measurable or evaluable disease per RECIST V1.1. Treatment group B: Presence of at least one two-dimensional measurable lesion confirmed by imaging (CT or MRI) (either lymph nodes lesions with any long diameter > 1.5 cm or extranodal lesions with any long diameter > 1.0 cm); for CLL patients whose baseline imaging evaluation determined that no two-dimensional measurable lesions, their peripheral blood monoclonal B lymphocytes should be ≥ 5.0×109/L.
5. Patients must provide archival tumor samples, or a biopsy will be required if archival tumor sample is not available. Archival tumor sample must be taken ≤ 2 years prior to screening, otherwise a fresh tumor biopsy at screening is required.
6. ECOG performance status 0 or 1
7. Adequate organ function to participate in the trial.
8. Recovery from adverse events (AEs) related to prior anticancer therapy.

Exclusion Criteria:

1. Prior treatment with any agent targeting ROR1.
2. History of Grade 4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies.
3. Patient with primary central nervous system (CNS) malignancy or symptomatic CNS metastases. Patients with solid tumors with CNS metastases are eligible if they do not need to receive local radiation treatment at the discretion of investigator or if radiation therapy for CNS metastases is completed ≥ 4 weeks prior to study treatment.
4. Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment.
5. Abuse on alcohol, cannabis-derived products, or other drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EMB-07-Patients with solid tumor; Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.	Drug: EMB07; EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Experimental: EMB07-Patients with lymphoma; Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.	Drug: EMB07; EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of adverse events as assessed by CTCAE V5.0.	Incidence and severity of AE.	Screening up to 30 days after the last dose.
Incidence of serious adverse events (SAE).	Incidence of SAE.	Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
Incidence of dose interruptions.	Incidence of dose interruptions of EMB-07 during treatment as a measure of tolerability.	Screening up to 30 days after the last dose.
Dose intensity.	Actual amount of drug taken by patients divided by the planned amount.	Screening up to 30 days after the last dose.
The incidence of DLTs during the first cycle of treatment.	The dose limiting toxicities are based on drug related adverse events and are specifically defined in study protocol.	First infusion to the end of cycle 1. (each cycle is 28 days).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the serum concentration-time curve (AUC) of EMB-07.	Blood samples for serum PK analysis will be obtained (AUC).	Through treatment until EOT visit, expected average 6 months.
Maximum serum concentration (Cmax) of EMB-07.	Blood samples for serum PK analysis will be obtained (Cmax).	Through treatment until EOT visit, expected average 6 months.
Trough concentration (Ctrough) of EMB-07.	Blood samples for serum PK analysis will be obtained (Ctrough).	Through treatment until EOT visit, expected average 6 months.
Average concentration over a dosing interval (Css, avg) of EMB-07.	Blood samples for serum PK analysis will be obtained (Css,avg).	Through treatment until EOT visit, expected average 6 months.
Terminal half-life (T1/2) of EMB-07.	Blood samples for serum PK analysis will be obtained (T1/2).	Through treatment until EOT visit, expected average 6 months.
Systemic clearance (CL) of EMB-07.	Blood samples for serum PK analysis will be obtained (CL).	Through treatment until EOT visit, expected average 6 months.
Steady state volume of distribution (Vss) of EMB-07.	Blood samples for serum PK analysis will be obtained (Vss).	Through treatment until EOT visit, expected average 6 months.
Incidence and titer of anti-drug antibodies stimulated by EMB-07.	Antibodies to EMB-07 will be assessed to evaluate potential immunogenicity.	Up to End of Treatment Follow Up Period (30 days after the last dose)
Overall response rate.	Overall response rate measured by RECIST V1.1, iWCLL-2018, Lugano 2014	From the date of dosing untill the date of first documented progression or date of death from any casue, whichever case first, expected average 6 months.
Progression free survival (PFS) of EMB-07 as assessed by RECIST 1.1, iWCLL-2018, Lugano 2014	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months.	Through treatment discontinuation: an average of 6 months

Collaborators and Investigators

• Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2023
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): March 31, 2026

Study Registration Dates

• First Submitted: October 27, 2022
• First Submitted That Met QC Criteria: November 3, 2022
• First Posted (Actual): November 7, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 28, 2025
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: Phase I; Dose escalation; ROR1; Bispecific antibody; Advanced/Metastatic Solid Tumors; CD3; EMB07; Relapse/Refractory Lymphoma
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease Attributes; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Recurrence; Lymphoma
• Other Study ID Numbers: EMB07X101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No